Status:
TERMINATED
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
Lead Sponsor:
Genmab
Conditions:
Head and Neck Cancer
Squamous Cell Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer
Eligibility Criteria
Inclusion
- Patients with locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx
Exclusion
- Prior treatment with radiotherapy in the head and neck area
- Prior treatment with chemotherapy
- Prior treatment with similar drugs (e.g. EGFr antibodies, EGFr inhibitors)
- Previous surgery with curative intent for head and neck cancer
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00401401
Start Date
December 1 2006
End Date
October 1 2010
Last Update
December 23 2011
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health Sciences Center
Portland, Oregon, United States, 97239
2
St-Luc University Hospital
Brussels, Belgium
3
University Hospital Gasthuisberg
Leuven, Belgium
4
Centre Georges-Francois Leclerc Hospital
Dijon, France